|
|
Publication
|
| Title of Article |
Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines |
| Date of Acceptance |
14 July 2020 |
| Journal |
| Title of Journal |
ANTICANCER RESEARCH |
| Standard |
ISI |
| Institute of Journal |
anticanres.14515 |
| ISBN/ISSN |
doi:10.21873 |
| Volume |
2020 |
| Issue |
40 |
| Month |
July |
| Year of Publication |
2020 |
| Page |
5115-5124 |
| Abstract |
Background/Aim: Pyruvate kinase M2 (PKM2) is an enzyme that is predominantly overexpressed in various types of cancer. The role of PKM2 in liver fluke-associated cholangiocarcinoma (CCA) remains unclear. This study aimed to investigate the antitumor activity of shikonin, a PKM2 inhibitor, in CCA cells. Materials and Methods: Immunohistochemistry and immunoblotting were used to determine PKM2 expression in CCA tissues and cells. Antiproliferative effects of shikonin were evaluated using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, colony-formation and trypan blue exclusion assays. The antimetastatic activity of shikonin was determined using the Boyden chamber assay. Mechanisms by which shikonin inhibited CCA progression were determined. Results: PKM2
was overexpressed in CCA compared to normal bile duct epithelial cells. Shikonin significantly inhibited growth, and migration of CCA cells while inducing their death. A mechanistic study revealed that antitumor effects of shikonin in CCA cells depended on increased production of reactive oxygen species. Conclusion: Shikonin may be a novel therapeutic agent for patients with CCA. |
| Keyword |
Cholangiocarcinoma, pyruvate kinase M2, shikonin, reactive oxygen species. |
| Author |
|
| Reviewing Status |
มีผู้ประเมินอิสระ |
| Status |
ตีพิมพ์แล้ว |
| Level of Publication |
นานาชาติ |
| citation |
true |
| Part of thesis |
true |
| Attach file |
|
| Citation |
0
|
|
|
|
|
|
|
|
|
Journal Publication
ไทย